HBV RNA destabilizers could potentially selectively impact HBV but not other RNA or DNA viruses and could as well demonstrate pan-genotypic antiviral activity. In addition, HBV RNA destabilizers have shown additive effects when provided in combination with anti-HBV agents having distinct mechanisms of action.
Our long-term strategy is to develop an all-oral combination treatment regimen to cure HBV which could potentially include an oral HBV RNA destabilizer in combination with a capsid inhibitor and an approved NA. AB-161 is currently in IND-enabling studies.